[Possibilities and limits of controlled clinical therapy studies for the demonstration of the effectiveness of antithrombotic therapy].
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004358:Drug Therapy / Q000592:standards; D004434:Early Ambulation; D005081:Exercise Therapy; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D026741:Physical Therapy Modalities / Q000592:standards; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D011187:Posture; D011655:Pulmonary Embolism / Q000188:drug therapy; D013300:Streptokinase / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control; D013927:Thrombosis / Q000628:therapy*
D000925:Anticoagulants; D003911:Dextrans; D004176:Dipyridamole; D005340:Fibrinogen; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin; D013442:Sulfinpyrazone
Möglichkeiten und Grenzen kontrollierter klinischer Therapiestudien zum Wirkungsnachweis antithrombotischer Therapie